Published on 17/12/2025
Nutritional Supplements and Herbal Products Registration – Pharmaceutical Regulatory Affairs
In today’s globalized market, the registration of nutritional supplements and herbal products requires a thorough understanding of country-specific regulations. In Colombia, this process is governed by INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos). This step-by-step guide provides essential insights into the regulatory framework necessary for the successful registration of these products. The focus will be on practical actions, documentation expectations, and adherence to best practices aligned with international guidelines.
Step 1: Understanding the Regulatory Framework in Colombia
The foundation of nutritional supplements and herbal products registration in Colombia lies within the regulatory framework established by INVIMA. Regulatory affairs professionals must grasp the various categories defined by INVIMA and the pertinent guidelines that govern each.
1.1. Categories of Products
- Nutritional Supplements: Products intended to supplement the diet, providing vitamins, minerals, or other nutrients.
- Herbal Products: Natural products derived from plants intended for therapeutic use or general health improvement.
1.2. Legislation and Guidelines
Colombia has
- Law 9 of 1979 – establishing basic health standards.
- Resolution 765 of 2012 – detailing the requirements for the registration of nutritional supplements.
Professionals must familiarize themselves with these and other relevant legislation. This understanding serves as the basis for preparing comprehensive dossiers and ensures compliance with INVIMA standards.
Step 2: Preparing the Dossier for Product Registration
Composing a thorough dossier is crucial for registration. The dossier must encompass all data and documents required to demonstrate product safety, efficacy, and quality. The structure of the dossier often aligns with the Common Technical Document (CTD) format, which is recognized internationally.
2.1. Dossier Components
- Administrative Information: This includes product name, applicant details, manufacturing site, and product uses.
- Quality Data (Module 3): Information on product formulation, stability studies, specifications, and quality control measures.
- Safety and Efficacy Data (Module 4): Clinical and non-clinical studies demonstrating safety and efficacy.
- Labeling and Packaging Information: Product labels must adhere to local advertising and labeling regulations.
2.2. Good Manufacturing Practices (GMP)
Manufacturers must adhere to Good Manufacturing Practices (GMP). INVIMA mandates compliance with GMP for all entities involved in the production of nutritional supplements and herbal products. Documentation must include quality management system procedures, facility layouts, and evidence of qualification of personnel and equipment.
Step 3: Submission of the Dossier to INVIMA
Once the dossier is structured, the next phase involves submission to INVIMA for evaluation. Understanding the submission process ensures a streamlined pathway and enhances the chances of timely approval.
3.1. Online Submission Process
INVIMA employs the Vía Web system for the electronic submission of medicinal product dossiers. Users must register on the platform and follow the instructions for dossier submission. Relevant documents must be uploaded in the defined format, providing ease in review.
3.2. Filing Fees
Submission fees are required and vary depending on the product type and validation needed. It’s critical for regulatory professionals to remain updated on the current fee structure provided by INVIMA, as these costs might influence operational budgets.
3.3. Acknowledgment of Receipt
Upon successful submission, INVIMA provides an acknowledgment of receipt, which should be stored as part of the product file. This confirmation initiates the review process and provides a tracking reference for the applicant.
Step 4: Review Process by INVIMA
The review process is a pivotal phase through which INVIMA assesses submitted applications. Understanding the detailed structure of this process is essential for managing applicant expectations and timelines.
4.1. Duration of Review
INVIMA aims to review submissions within a specific timeframe, usually within 30 to 60 days, although complex dossiers may take longer. Regulatory affairs professionals should plan for possible queries or requests for additional information during this period.
4.2. Regulatory Queries
During the review, INVIMA may issue queries regarding specific aspects of the dossier. Prompt and adequate responses are crucial to keep the application moving forward. Teams must prepare to address questions regarding safety, efficacy, or documentation.
4.3. Approval or Rejection
After the evaluation process, INVIMA will either grant approval, request additional documentation, or issue a rejection notice. In the case of rejection, the notification must include reasons, guiding the applicant in addressing concerns for future submissions.
Step 5: Post-Approval Activities and Compliance Monitoring
After successfully obtaining market authorization, companies must navigate the realm of post-approval activities to maintain compliance with INVIMA regulations. This phase involves critical responsibilities regarding product monitoring and reporting.
5.1. Pharmacovigilance Requirements
Pharmacovigilance is an essential element for ensuring ongoing safety throughout the product’s lifecycle. Companies must establish robust systems for monitoring adverse effects and reporting them as part of their regulatory compliance obligations.
5.2. Periodic Safety Update Reports (PSURs)
As part of pharmacovigilance, companies are required to submit PSURs at defined intervals, which summarize the safety profile of the product. These reports must be prepared meticulously to reflect the latest safety data and risk assessments.
5.3. GMP Compliance After Approval
Maintaining compliance with GMP after product launch is vital. Regular audits of the manufacturing facility must be conducted to ensure adherence to quality standards. Non-compliance can lead to sanctions or revocation of product registration.
Step 6: Market Surveillance and Enforcement Actions
The final stage involves understanding the role of INVIMA in monitoring products post-approval to ensure that they remain compliant with health standards and regulations.
6.1. Market Surveillance Programs
INVIMA conducts routine inspections and monitoring of products in the marketplace to ensure they meet safety and quality standards. They may take samples for quality analysis, and companies must support these efforts through cooperation and transparency.
6.2. Enforcement Actions
In instances of non-compliance, INVIMA can initiate enforcement actions that may include market withdrawal, recalls, or production halts. Regulatory affairs professionals must proactively engage in risk management practices to mitigate potential issues that could trigger these actions.
Staying informed about regulatory changes and engaging directly with regulatory authorities is imperative for maintaining a proactive stance in market compliance.
Conclusion
Understanding the regulatory landscape surrounding the registration of nutritional supplements and herbal products in Colombia is essential for professionals in pharmaceutical regulatory affairs. By following a structured approach—from understanding regulations, dossier preparation, and submission, to navigating the review process and ensuring compliance post-approval—companies can effectively manage the complexities of INVIMA’s requirements. This comprehensive guide serves as a practical tool for professionals dedicated to adhering to the highest standards of regulatory excellence.